2seventy bio, Inc. (TSVT) upgraded to Zacks Rank #2 (Buy) due to positive earnings estimates trend.

From Nasdaq: 2024-12-04 12:00:12

2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system focuses on earnings picture changes, with rising estimates indicating positive stock price movement potential. Institutional investors also use earnings estimates to calculate fair value and influence stock prices.

The Zacks Rank system, which classifies stocks based on earnings estimates, has a strong track record of success. Stocks with Zacks Rank #1 have averaged a +25% annual return since 1988. 2seventy bio, Inc. is expected to earn -$0.50 per share for the fiscal year ending December 2024, with a 42.5% increase in consensus estimates over the past three months.

2seventy bio, Inc.’s upgrade to a Zacks Rank #2 places it in the top 20% of Zacks-covered stocks for estimate revisions, indicating potential for near-term stock price growth. Zacks Research Chief has identified 5 stocks likely to double, with one financial firm showing promising gains. This top pick boasts innovative solutions and a growing customer base, potentially surpassing previous Zacks’ top performers.



Read more at Nasdaq: 2seventy bio, Inc. (TSVT) Upgraded to Buy: Here’s What You Should Know